Related Experiment Videos
Bestatin administration and the change in cellular immunity
12nd Dept of Surgery, Kyoto Prefectural University of Medicine, Japan.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1991
Summary
Bestatin (ubenimex) treatment improved cellular immunity in gastrointestinal cancer patients. It boosted T cell counts, enhanced immune responses, and increased interleukin-2 (IL-2) receptor levels, suggesting a potential immunomodulatory role.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Gastrointestinal cancers often involve complex immune dysregulation.
- Modulating cellular immunity is a key strategy in cancer therapy.
- Bestatin (ubenimex) is an immunomodulatory drug with potential anticancer applications.
Purpose of the Study:
- To evaluate the effects of Bestatin on cellular immunity in patients with gastrointestinal cancer.
- To assess changes in T cell subsets, IL-2 receptor expression, and immune reactivity.
Main Methods:
- A study involving 23 gastrointestinal cancer patients treated with oral Bestatin (30 mg/day).
- Assessment of functional T cell subsets (helper, cytotoxic, suppressor).
- Measurement of interleukin-2 (IL-2) receptor levels, PHA-induced blastogenesis, and PPD skin reactions.
Main Results:
- Increased absolute numbers of helper T cells (74%) and cytotoxic T cells (79%).
- Decreased absolute numbers of suppressor T cells (79%).
- Elevated IL-2 receptor levels (56%), PHA blastogenesis (67%), and PPD skin reactions (75%) compared to pretreatment values.
Conclusions:
- Bestatin treatment significantly enhanced cellular immunity in gastrointestinal cancer patients.
- The drug appears to modulate T cell populations and improve immune responses.
- These findings support Bestatin's potential as an immunotherapeutic agent in oncology.